MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

Rhea-AI Summary

MiNK Therapeutics, a biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on December 1st at 4:45 PM ET. The event will be accessible live via a provided link, with a replay available on the MiNK website afterward. Recently, MiNK presented new data from five presentations at the Society for Immunotherapy of Cancer Annual Meeting on November 10th, showcasing their innovative iNKT cell therapies aimed at treating cancer and immune-mediated diseases.

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5^th Annual Evercore ISI HealthCONx Conference on Thursday December 1^st, at 4:45 PM ET.

Access to the live fireside chat is available at https://wsw.com/webcast/evercore29/inkt/2382660. A replay will be available after the call on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations.

MiNK recently presented new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10^th. These presentations are available on the MiNK website at https://minktherapeutics.com/publications/.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.

Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

What is MiNK Therapeutics participating in on December 1st, 2022?

MiNK Therapeutics will participate in the 5th Annual Evercore ISI HealthCONx Conference.

Who is the CEO of MiNK Therapeutics?

Dr. Jennifer Buell is the President and CEO of MiNK Therapeutics.

What time is the fireside chat at the Evercore ISI HealthCONx Conference?

The fireside chat is scheduled for 4:45 PM ET on December 1st, 2022.

Where can I watch the MiNK Therapeutics fireside chat?

The fireside chat can be accessed live through a specified link and will be replayed later on the MiNK website.

What significant presentation did MiNK Therapeutics make on November 10th, 2022?

MiNK presented new data related to their iNKT cell therapies at the Society for Immunotherapy of Cancer Annual Meeting.